Study #2023-0590
Immunogenicity and clinical efficacy of 20-valent pneumococcal conjugate vaccine (PCV20) in lymphoma survivors after treatment with anti-CD20 therapy.
MD Anderson Study Status
Not Accepting
Treatment Agent
PCV20
Description
To compare the effects of a pneumococcal vaccine called PCV20 when given as a single dose versus a boosted regimen to patients who previously received anti-CD20 therapy as treatment for B cell lymphoma.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Lymphoma
Study phase:
Phase IV
Physician name:
Fareed Khawaja
Department:
Infectious Diseases
For general questions about clinical trials:
1-833-391-3015
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.